Emerging data suggest Retatru tide , a dual agonist targeting both GLP-1 and another hormone, appears to provide a significant step forward for body management . Preliminary patient investigations have indicated considerable losses in abdominal tissue, possibly outperforming current weight-loss therapies . Despite this, more evaluation is required